Actionable mutations in pancreatic cancer: where targeted therapies are making a difference
{{output}}
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid tumours, with 5-year survival consistently below 10% and only modest gains from conventional chemotherapy after first-line failure. Although oncogenic KRAS mutations dominate the genomi... ...
